Patent Eligibility For Biotech Inventions.
I. Introduction: Biotech Patentability
Biotechnology inventions often involve genes, proteins, DNA sequences, microorganisms, and biotech processes. Patent eligibility depends on satisfying the standard criteria of:
Patentable subject matter
Novelty
Inventive step / non-obviousness
Industrial applicability
Sufficient disclosure
Challenges unique to biotech inventions:
Natural discoveries vs human-made inventions
Ethical and public policy concerns
Scope of gene and protein patents
Ownership of living organisms and microbiological processes
In India, biotech patentability is governed by Section 3(c), 3(d), 3(j), and 3(i) of the Patents Act 1970. Globally, EPC (Europe) and US patent law have specific rules for biotech inventions.
II. Patent Eligibility Criteria for Biotech Inventions
1. Patentable Subject Matter
Must be man-made or isolated from nature with human ingenuity.
Pure discoveries of genes, proteins, or natural processes are generally not patentable.
Isolated DNA, modified organisms, or recombinant proteins may be patentable.
2. Novelty
Must be new worldwide.
Prior publication, natural occurrence, or prior use destroys novelty.
3. Inventive Step / Non-Obviousness
Must not be obvious to a person skilled in biotechnology.
Must solve a technical problem.
4. Industrial Applicability
Must have practical application in medicine, agriculture, or industry.
5. Sufficiency of Disclosure
Must disclose the invention fully, including sequences or processes, so that skilled persons can reproduce it.
III. Key Case Laws
1. Diamond v. Chakrabarty (US, 1980)
Facts:
Genetically engineered bacterium capable of breaking down crude oil.
Patentee sought a patent on living microorganism.
Court Findings:
US Supreme Court held: “anything under the sun made by man” is patentable, including genetically engineered organisms.
Natural bacteria are not patentable, but human-modified organisms are.
Principle:
Human ingenuity transforms natural organisms into patentable inventions.
2. Myriad Genetics Inc. v. Association for Molecular Pathology (US, 2013)
Facts:
Patents claimed isolated DNA sequences (BRCA1 and BRCA2 genes).
Court Findings:
Naturally occurring DNA sequences cannot be patented.
cDNA (synthetic complementary DNA) is patentable because it is not naturally occurring.
Principle:
Discovery of natural gene is not patentable, but modified/synthetic sequences are.
3. Biogen v. Medeva (UK, 1997)
Facts:
Patent for a method to produce therapeutic protein using recombinant DNA.
Court Findings:
Patent was valid because it involved technical application of knowledge.
Method provided industrial applicability and was inventive.
Principle:
Biotech processes involving technical application of genetic engineering are patentable.
4. Harvard Mouse Case (US, 1988 – Oncomouse)
Facts:
Harvard developed a genetically modified mouse susceptible to cancer.
Findings:
US granted patent; Europe initially refused, then granted under strict ethical and technical limitations.
Principle:
Genetically modified higher animals can be patented if human intervention is demonstrated.
Raises ethical limitations in Europe, e.g., animal welfare exclusions.
5. Monsanto v. Nuziveedu Seeds (India, 2016)
Facts:
Monsanto held patents for Bt cotton seeds.
Indian farmers allegedly used patented seeds without license.
Court Findings:
Indian courts upheld patent rights in genetically modified seeds, provided technology is novel, inventive, and industrially applicable.
Section 3(j) of Indian Patents Act excludes plants and seeds per se, but the biotechnological process is patentable.
Principle:
Process-based patent protection is allowed for biotech in India, even if the product is naturally derived.
6. Novartis v. Union of India (Gleevec Case, 2013)
Facts:
Novartis sought patent for beta-crystalline form of Imatinib (Gleevec) drug.
Findings:
Patent rejected under Section 3(d) (new form of known substance).
Mere enhancement in efficacy is insufficient; must be significant inventive step.
Principle:
Incremental improvements in biotech/pharmaceutical inventions are scrutinized for genuine inventive step.
7. Chiron Corp v. Genentech (US, 1996)
Facts:
Patents claimed recombinant hepatitis B vaccine.
Findings:
Court upheld patent because recombinant process and isolated proteins were technically inventive.
Principle:
Recombinant proteins and vaccine processes are patentable if human ingenuity is involved.
IV. Observations
Human intervention is critical – natural genes or organisms are not patentable.
Biotechnological processes are patentable if novel, inventive, and industrially applicable.
Ethical and public policy limits apply, particularly for higher animals.
India vs US vs Europe – India excludes plants, seeds, and incremental modifications without inventive step.
Patent claims must be precise – disclose sequences, constructs, or methods clearly.
V. Practical Guidelines for Biotech Patents
Claim human-modified products, not natural discoveries.
Document industrial applicability for therapeutic, agricultural, or industrial use.
Demonstrate inventive step over prior art.
Ensure sufficient disclosure of sequences, processes, or constructs.
Consider jurisdictional differences – US allows broader patent scope; India is restrictive on natural forms.
Key Takeaway:
Biotech inventions are patentable if they involve human intervention, technical application, and meet novelty, inventive step, and industrial applicability criteria. Mere discoveries of natural genes, proteins, or organisms are generally not patentable, though synthetic or modified forms are.
RELATED Blog
comments